FDA SETS ASIDE JULY 28 FOR ADDITIONAL ZOVIRAX Rx-TO-OTC SWITCH REVIEW; DUAL Rx/OTC STATUS SUGGESTED AS WAY OF KEEPING INSURANCE COVERAGE BY AMWA
Burroughs Wellcome's antiviral Zovirax has been allotted additional time by FDA for a July 28 review of its potential Rx- to-OTC switch by the agency's Nonprescription Drugs Advisory Committee and the Antiviral Drugs Advisory Committee, according to a tentative list of advisory committee meeting dates.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth